H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aptose Biosciences (APTO – Research Report) today and set a price target of $9.00. The company’s shares closed last Tuesday at $2.63, close to its 52-week low of $2.55.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 25.4% and a 43.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $10.43 average price target.
Based on Aptose Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.23 million. In comparison, last year the company had a GAAP net loss of $11.53 million.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.